Critical reagents for ligand-binding assays: process development methodologies to enable high-quality reagents

Area of Science:

• Biopharmaceutical Development
• Analytical Chemistry
• Assay Development

Background:

• Biotherapeutic development necessitates robust pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity assays, often utilizing ligand-binding assay (LBA) formats.
• Conjugated critical reagents, formed by linking biotherapeutics or anti-drug antibodies with labels, are essential for LBA performance.
• The quality of these conjugated reagents directly influences LBA reliability, underscoring the need for stringent process control during their generation.

Purpose of the Study:

• To advocate for the integration of process development methodologies into the production of conjugated critical reagents for LBAs.
• To elucidate the impact of conjugation reactions, purification techniques, and formulation conditions on the quality of critical reagents.
• To present a practical approach for developing robust process conditions for various molecular classes of critical reagents.

Main Methods:

• Application of process development methodologies to critical reagent production.
• Case studies demonstrating the development of process conditions for antibody and peptide-based critical reagents.
• Evaluation of conjugation chemistry, purification strategies, and formulation parameters.

Main Results:

• Demonstrated successful development of process conditions for generating conjugated critical reagents.
• Case studies provided insights into optimizing reagent quality for different molecular types (antibodies, peptides).
• The developed approach offers a framework for consistent and reliable critical reagent production.

Conclusions:

• Integrating process development into critical reagent generation is crucial for ensuring LBA performance and biotherapeutic quality control.
• The presented methodologies and case studies offer a scalable approach for producing high-quality conjugated critical reagents.
• This strategy supports the reliable development and manufacturing of future biotherapeutics.